Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
Critical care
See all tags

MTRC released the report on reimbursement of diagnostic testing for COVID-19 in Europe

COVID-19 pandemic seriously affected European countries. One of the key aspects of managing the epidemic is the timely testing of potentially infected people. 

This report summarizes the reimbursement situation for COVID-19 in European countries with established reimbursement framework for in-vitro diagnostic tests (Belgium, France, Germany, Netherlands, Switzerland and Turkey).

The 26-page report answers the following question:

  • Is there any reimbursement for IVD testing for COVID-19?
  • What kind of tests (e.g. PCR or serology) are reimbursed?
  • What are the reimbursement tariffs?
  • Are there any restrictions for testing? 

Order sample pages and learn more here.

Tags
Services of MTRC
In-vitro diagnostic tests

The latest related news

20
Dec 2024

Regular update of the Norwegian Laboratory Code System released

On November 23, 2024, the Norwegian Directorate of Health released an updated version of the Norwegian Laboratory Code (NLK) system and associated tariffs to be implemented no later than January 1, 2025. Thirty-two new codes were added in the biochemistry, microbiology, clinical pharmacology, and immunology fields.
Read more
13
Dec 2024

Bi-weekly snapshot of market access and HEOR project work at MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 16th of December, we plan to work on 20 projects. Review the complete list of planned activities in this post.
Read more
05
Dec 2024

Updates in the coverage of medical services in Switzerland in 2025

On December 2, 2024, the Swiss Federal Office of Public Health published the changes that will occur to the Healthcare Benefit Ordinance (KLV/OPre), which determines coverage of medical services in Switzerland. The updates will enter into force on January 1, 2025, and they relate to the list of explicitly evaluated services (Annex 1 of KLV/OPre), outpatient-before-hospital services (Annex 1a), List of Tools and Equipment (Annex 2), and the List of Analyses (Annex 3).
Read more